Back to Search Start Over

Secondary Prevention of Stroke with Atrial Fibrillation by New Oral Anticoagulants

Secondary Prevention of Stroke with Atrial Fibrillation by New Oral Anticoagulants

Authors :
K. Kamiyama
Hirohiko Nakamura
T. Osato
Source :
Treatment of Non-vitamin K Antagonist Oral Anticoagulants ISBN: 9789811018770
Publication Year :
2016
Publisher :
Springer Singapore, 2016.

Abstract

We used the results of secondary prevention analyses for patients with a history of stroke or TIA in the large-scale RE-LY, ROCKET-AF (J-ROCKET-AF), and ARISTOTLE clinical trials to investigate the choice of new oral anticoagulants (NOACs) to prevent recurrent stroke. In light of these results, we concluded that dabigatran 150 mg BID should be the first-choice treatment for comparatively young patients with no apparent renal dysfunction, and apixaban for other patients, and that their efficacy and safety can be broadly guaranteed.

Details

ISBN :
978-981-10-1877-0
ISBNs :
9789811018770
Database :
OpenAIRE
Journal :
Treatment of Non-vitamin K Antagonist Oral Anticoagulants ISBN: 9789811018770
Accession number :
edsair.doi...........6087cc6d91cdedab377af9d12f69b1f9
Full Text :
https://doi.org/10.1007/978-981-10-1878-7_1